戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 r deliver drugs systemically without hepatic first pass metabolism.
2 substrates that undergo extensive intestinal first-pass metabolism.
3 , by inhibiting intestinal (but not hepatic) first-pass metabolism.
4 f verapamil, a drug that undergoes extensive first-pass metabolism.
5 ufficient alcohol to account for the bulk of first-pass metabolism.
6 sm in keeping with its inhibition of in vivo first-pass metabolism.
7 ministered alcohol is incomplete, indicating first-pass metabolism.
8 ch has the metabolic capacity to account for first-pass metabolism.
9 vir to enhance bioavailability by overcoming first-pass metabolism.
10 , which should be drugged topically to avoid first-pass metabolism.
11  a rapid onset of action while bypassing the first-pass metabolism.
12 ain barrier-permeant, but suffers from rapid first-pass metabolism.
13 okinetics are remarkable for almost complete first pass metabolism after oral administration, resulti
14                  Based on this difference in first pass metabolism, an increase of 2% in bioavailabil
15 dation in gastrointestinal tract and hepatic first pass metabolism and also limits off-target adverse
16 and extensive distal binding in all tissues, first-pass metabolism and activation of NNK in the airwa
17             Intranasal administration avoids first-pass metabolism and provides a reproducible, easil
18        There is debate regarding the site of first-pass metabolism and specifically whether the stoma
19 their poor absorption, poor solubility, high first-pass metabolism, and efficient efflux by P-glycopr
20               Astemizole undergoes extensive first-pass metabolism, and its dominant metabolite, desm
21 ing non-invasive alternative, as it bypasses first-pass metabolism, avoids gastrointestinal degradati
22 ug delivery systems as films not only avoids first-pass metabolism, but also provides pain-free admin
23 azole, 8.0% of the tacrolimus dose underwent first pass metabolism (E(H)), whereas in the presence of
24 rful new tool for preclinical predictions of first-pass metabolism for new drugs in development.
25 aempferol to cultured hepatocytes, mimicking first pass metabolism, greatly diminished the inhibitory
26 of developing solid and liquid dosage forms, first-pass metabolism, high dosing frequency translating
27 thanol from reaching the liver by activating first-pass metabolism in the stomach.
28                                              First-pass metabolism is a common cause of incomplete an
29  as inhibition of liver CYPs responsible for first pass metabolism, make selective inhibition a high
30 aining monooxygenase enzymes involved in the first-pass metabolism of drugs and foreign chemicals in
31                 The effect of glycine on the first-pass metabolism of ethanol was also examined in vi
32                                          The first-pass metabolism of foreign compounds in the lung i
33 tients with TIPS, there was a marked loss in first-pass metabolism of midazolam as a result of dimini
34  intestinal P450 expression and capacity for first-pass metabolism of oral drugs.
35 en et al. show in this issue of the JCI that first-pass metabolism of the anticancer agent docetaxel
36  and poor oral bioavailability, due to rapid first-pass metabolism of the phenol moieties.
37 9 was not active orally, likely due to rapid first-pass metabolism of the phenol moiety.
38 y influencing either the absorption phase or first-pass metabolism of TVR.
39 henols undergo extensive modification during first-pass metabolism so that the forms reaching the blo
40 )), whereas in the presence of ketoconazole, first pass metabolism was 6.2% (P=0.01).